Rossmore Private Capital Arvinas, Inc. Transaction History

Rossmore Private Capital

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	SELL	$26.15 - $37.26 $492,064 - $701,121	-18,817 Reduced 56.78%	14,322 $391,000
Q3 2022 Nov 07, 2022	SELL	$41.87 - $57.99 $1.39 Million - $1.92 Million	-33,139 Reduced 50.0%	33,139 $1.47 Million
Q1 2022 May 09, 2022	SELL	$60.27 - $81.57 $265,850 - $359,805	-4,411 Reduced 6.24%	66,278 $4.46 Million
Q3 2021 Nov 08, 2021	SELL	$73.2 - $107.87 $667,291 - $983,342	-9,116 Reduced 11.42%	70,689 $5.81 Million
Q1 2021 May 10, 2021	SELL	$58.19 - $91.37 $1.12 Million - $1.76 Million	-19,210 Reduced 19.4%	79,805 $5.28 Million
Q4 2020 Feb 10, 2021	SELL	$20.19 - $84.93 $20,190 - $84,930	-1,000 Reduced 1.0%	99,015 $8.41 Million
Q2 2020 Aug 05, 2020	SELL	$29.88 - $56.74 $285,354 - $541,867	-9,550 Reduced 8.72%	100,015 $3.36 Million
Q1 2020 May 07, 2020	SELL	$33.0 - $54.5 $968,517 - $1.6 Million	-29,349 Reduced 21.13%	109,565 $4.42 Million
Q4 2019 Feb 10, 2020	BUY	$15.39 - $44.38 $2.14 Million - $6.17 Million	138,914 New	138,914 $5.71 Million

221

68.8M

166K

31.3K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.44B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Rossmore Private Capital, based on Form 13F filings with the SEC.

Stay updated on Rossmore Private Capital with notifications on news.